AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21995388
Drug: Control (noninfluenza)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (noninfluenza) vaccines
Trial: 15625793
Drug: Habituation-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habituation-based treatment (5 sessions)
Trial: 11048414
Drug: Cefazolin administration
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administration (1 mg i.v. after ligation of the umbilical cord)
Trial: 11048414
Drug: Cefazolin administration
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administration
Trial: 2256055
Drug: l-selenium-methionine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-selenium-methionine (200 micrograms daily)
Trial: 2256055
Drug: peaselenium (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peaselenium (200 micrograms daily)
Trial: 6170414
Drug: L-6 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-6 regimen (control)
Trial: 6170414
Drug: L-12 protocol
RxNorm normalized name: L-cis-1,2-epoxypropylphosphonic acid
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-12 protocol
Trial: 6170414
Drug: L-6 protocol
RxNorm normalized name: 6-ammonio-L-norleucine
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-6 protocol (control)
Trial: 25426541
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (9.3 g of protein/566.4 KJ) plus exercise
Trial: 23602843
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment (ET) with dextranomer hyaluronic acid copolymer (Dx/HA)
Trial: 21093286
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil dietary supplementation, 6 g/day (720 mg of DHA and 1,080 mg of EPA)
Trial: 19436226
Drug: 0.25% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% DHEA (Prasterone) 1.3 mL ovules
Trial: 19436226
Drug: 0.5% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% DHEA (Prasterone) 1.3 mL ovules
Trial: 19436226
Drug: 1.0% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0% DHEA (Prasterone) 1.3 mL ovules
Trial: 15540634
Drug: Neurodevelopmental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental treatment (NDT) twice a week for 16 weeks
Trial: 15540634
Drug: Neurodevelopmental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental treatment (NDT) five times a week for 16 weeks
Trial: 9646600
Drug: Extended outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended outpatient treatment of 180 days
Trial: 9646600
Drug: Regular outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular outpatient treatment of 90 days
Trial: 20701567
Drug: Traditional Indigenous
RxNorm normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Indigenous Games (TIG) delivered weekly for three months
Trial: 14656033
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid (5 mg/day)
Trial: 8633144
Drug: 2 mL/sec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL/sec
Trial: 8633144
Drug: 3 mL/sec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL/sec
Trial: 8633144
Drug: 4.5 mL/sec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mL/sec
Trial: 8633144
Drug: 6 mL/sec
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mL/sec
Trial: 1424880
Drug: Formoterol suspension
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol suspension aerosol (12 micrograms, twice daily)
Trial: 1424880
Drug: Formoterol solution
RxNorm normalized name: formoterol Inhalation Solution
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol solution aerosol (12 micrograms, twice daily)
Trial: 2933119
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tetracycline and oestrogen‐cyproterone acetate
Trial: 30527419
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate therapy
Trial: 3096181
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sodium bicarbonate therapy)
Trial: 21141077
Drug: Long-acting carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting carteolol hydrochloride 2% ophthalmic solution (LA), administered once a day
Trial: 21141077
Drug: Original carteolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original carteolol hydrochloride 2% ophthalmic solution (CA), administered twice a day
Trial: 17068328
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin on alternate days
Trial: 16140593
Drug: Topiramate (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (200-400 mg/day for adults or 5-9 mg/kg/day for children)
Trial: 12145765
Drug: Vehicle (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (300 mL water with noncaloric flavoring)
Trial: 7638685
Drug: Very-low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-low-protein diet (0.4 g protein/kg/day supplemented with essential amino acids)
Trial: 7638685
Drug: Conventional low-protein
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional low-protein diet (0.6 g protein/kg/day)
Trial: 11994055
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C
Trial: 576879
Drug: All Treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All Treatments
Trial: 25722381
Drug: Trametinib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (2 mg orally once daily)
Trial: 25722381
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 i.v. every 3 weeks)
Trial: 21235774
Drug: Mobile Cognitive
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile Cognitive Therapy (M-CT) in addition to treatment as usual (TAU)
Trial: 19586231
Drug: Day treatment,
RxNorm normalized name: Coartem 3-Day Treatment, 6 Tablet Blister Card
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment, abstinence-contingent housing, and vocational training (various combinations)
Trial: 17584549
Drug: High-bolus-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-bolus-dose tirofiban (25 microg/kg over 3 minutes, followed by 0.15 microg/kg per minute for 18 to 24 hours)
Trial: 7865492
Drug: CBS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS and metronidazole double therapy
Trial: 7865492
Drug: CBS, metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS, metronidazole and amoxicillin triple therapy
Trial: 81218
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy and cytoreductive surgery
Trial: 30030134
Drug: Intervention (targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (targeted combination intervention)
Trial: 22219060
Drug: Specific exercise
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific exercise program (9 exercises for lumbar region, executed daily for 8 minutes)
Trial: 20737584
Drug: Dipyridamole (0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.56 mg/kg i.c.)
Trial: 20737584
Drug: Verapamil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (1 mg i.c.)
Trial: 18621929
Drug: Extracorporeal photopheresis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal photopheresis (ECP) and standard therapy
Trial: 13679675
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (300 ml for two weeks)
Trial: 13679675
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (300 ml for two weeks)
Trial: 8777337
Drug: alpha interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha interferon therapy for 4 months
Trial: 1836220
Drug: Fosinopril 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 5 mg, increased to 10 mg if DBP > 95 mmHg, administered orally once daily for 4 weeks
Trial: 1836220
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg, increased to 50 mg if DBP > 95 mmHg, administered orally once daily for 4 weeks
Trial: 6316670
Drug: Cefotaxime treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime treatment
Trial: 25341673
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide injection (first injection)
Trial: 25341673
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide injection (second injection)
Trial: 25341673
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide injection (third injection)
Trial: 25341673
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid and NaCl injections
Trial: 18809799
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for PMR with coronary artery bypass graft
Trial: 18809799
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for PMR
Trial: 12392825
Drug: Acetylcysteine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (400 mg orally twice daily) and 0.45% saline intravenously
Trial: 2179754
Drug: Ciclosporin (CS)
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin (CS) 5‐8 mg/kg/24 h and warfarin
Trial: 7152084
Drug: Aludrox tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aludrox tablets for the first 2 weeks
Trial: 7152084
Drug: Aludrox tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aludrox tablets
Trial: 30975121
Drug: Combined smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined smoking with the highest exposure dose
Trial: 21328434
Drug: DTI titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTI titration protocol (argatroban or bivalirudin)
Trial: 20554370
Drug: aceclofenac 100mg-drotaverine
RxNorm normalized name: aceclofenac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aceclofenac 100mg-drotaverine 80 mg b.i.d
Trial: 16118805
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autologous stem cell support (HDC)
Trial: 16118805
Drug: Intermediate-dose chemotherapy
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose chemotherapy (IDC)
Trial: 11772910
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg glyburide orally
Trial: 10189518
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of nimodipine
Trial: 10189518
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of nimodipine
Trial: 2182437
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy (including doxorubicin intensification with or without asparaginase)
Trial: 2182437
Drug: Less intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intensive chemotherapy
Trial: 27424036
Drug: Prednisone 2.5-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 2.5-60 mg daily for 7 days
Trial: 22500844
Drug: Metformin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1500 mg/day plus Calcium 1000 mg/day and Vitamin D 100000 IU/month for 6 months
Trial: 18562162
Drug: HR-titrated beta-blocker
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HR-titrated beta-blocker dosing regimen
Trial: 18562162
Drug: Fixed-dose beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose beta-blocker dosing regimen
Trial: 17609401
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy (administered every 14 days for 12 weeks)
Trial: 2689986
Drug: F 1.8
RxNorm normalized name: Gelato APF 1.81 % Dental Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F 1.8 formula (1.8 g protein/100 mL)
Trial: 2689986
Drug: F 1.3
RxNorm normalized name: Kaochlor S-F 1.33 MEQ/ML Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F 1.3 formula (1.3 g protein/100 mL)
Trial: 19358498
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment at Tinghui (GB 2), Yifeng (TE 17), Hegu (LI 4), Xiaxi (GB 43), Zhongzhu (TE 3)
Trial: 19358498
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group with intravenous 6% low molecule dextran 500 mL with ATP and coenzyme A, and oral Nimodipine, Gold Theragan
Trial: 16935718
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT scans at 15 mA
Trial: 16935718
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT scans (tube current < 15 mA) with edge-preserving smoothing filter
Trial: 16935718
Drug: High-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CT scans (55 mA)
Trial: 2897780
Drug: bevantolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bevantolol (200 to 400 mg)
Trial: 28110896
Drug: mepolizumab 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepolizumab 75 mg IV
Trial: 28110896
Drug: mepolizumab 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepolizumab 75 mg IV and SC
Trial: 24094008
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no orthodontic treatment (n = 14)
Trial: 16510488
Drug: Non-drug users
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug users
Trial: 2107060
Drug: Niflumic acid
RxNorm normalized name: niflumic acid
DrugBank: Niflumic acid (DB04552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niflumic acid (4 capsules of 250 mg daily)
Trial: 6626105
Drug: Self-controlled exposure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-controlled exposure (Post-treatment)
Trial: 31501084
Drug: early salvage
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: early salvage radiotherapy (eSRT) initiated at PSA <0.5 ng/ml
Trial: 31501084
Drug: late salvage
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: late salvage radiotherapy (lSRT) initiated at PSA ≥0.5 ng/ml
Trial: 12385435
Drug: B-LAC (bismuth,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-LAC (bismuth, clarithromycin, amoxicillin, and lansoprazole)
Trial: 12385435
Drug: B-LAA (bismuth,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-LAA (bismuth, azithromycin, amoxicillin, and lansoprazole)
Trial: 10442379
Drug: Endocrine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine plus UFT therapy
Trial: 7605858
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg/day for 10 weeks, tapered to 6 mg/day after 8 weeks)
Trial: 7605858
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg/day for 10 weeks, tapered to 5 mg/day after 2 weeks)
Trial: 7605858
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Budesonide and Prednisolone)
Trial: 498413
Drug: Daunorubicin (1.0‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (1.0‐1.5 mg/kg) as the free drug (for 45 min or 4 h)
Trial: 31227307
Drug: Sunitinib followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib followed by deferred CN 24h after the last dose of sunitinib
Trial: 28202686
Drug: Simvastatin pre-treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin pre-treatment
Trial: 28202686
Drug: Simvastatin post-treatment
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simvastatin post-treatment
Trial: 28202686
Drug: Simvastatin pre-treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin pre-treatment and post-treatment
Trial: 25851020
Drug: Ropivacaine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine infusion via saphenous catheter
Trial: 25851020
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline infusion via saphenous catheter
Trial: 20842754
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root powder capsules
Trial: 17490569
Drug: Soluvit treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluvit treatment
Trial: 17490569
Drug: Control (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (500 ml normal saline infusion)
Trial: 15472178
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 0.074 mg/kg, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Trial: 15472178
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Trial: 7828383
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment for 4 weeks
Trial: 527635
Drug: Codeine 20
RxNorm normalized name: codeine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 20 mg
Trial: 527635
Drug: Noscapine 30
RxNorm normalized name: noscapine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noscapine 30 mg
Trial: 30873102
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (control group–CG)
Trial: 22086510
Drug: Long-axis free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-axis free hand (L-FH)
Trial: 20638463
Drug: N-Acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetyl-cysteine (NAC) 1200 mg/day for 14 days
Trial: 9751064
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone (1000 microg/day)
Trial: 28479257
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (LB) with a bridge of 30 mL of 0.5% bupivacaine
Trial: 24535359
Drug: dezocine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dezocine (0.1 mg/kg)
Trial: 24535359
Drug: flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flurbiprofen axetil (1 mg/kg)
Trial: 23063354
Drug: FLOT (infusional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT (infusional 5‐FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m(2))
Trial: 20739846
Drug: Adjuvant interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant interferon (IFN) therapy
Trial: 18379536
Drug: AA-containing peritoneal
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA-containing peritoneal dialysis solution